Archana Chatterjee - Concepedia

Author

Archana Chatterjee

Also Known As

A Chatterjee, A. Chatterjee, Archana Chatterjee, Chatterjee A, Chatterjee, Archana, Costa Rica HPV Vaccine Trial and the PATRICIA study groups, Kari Simonsen, Satyaranjan Behera

153

Publications

5.2K

Citations

H-Index

104

Concepts

All Affiliations

University of South Dakota Creighton University Sanford Children's Specialty Clinic GlaxoSmithKline (Belgium)CHI Health Creighton University Medical Center - Bergan Mercy

About

Archana Chatterjee is an author at University of South Dakota specializing in medicine, public health, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	17	1.2K
2	Engineering	2	2	31
3	Health Sciences	1	1	161
4	Law	1	1	16
5	Natural Sciences	1	1	35

Archana Chatterjee

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years Mark H. Einstein, Mira Baron, Myron J. Levin, Human Vaccines	2009	396
Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics Charles R. Woods, John S. Bradley, Archana Chatterjee, Journal of the Pediatric Infectious Diseases Society	2021	242
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study Cosette M. Wheeler, S. Rachel Skinner, Maria Rowena Del Rosario‐Raymundo, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccinologyViviane StudyPrecancerous Lesions	2016	187
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study S. Rachel Skinner, Anne Szarewski, Barbara Romanowski, The Lancet VaccinationVaccine SafetyVaccinologyViviane StudyPrecancerous Lesions	2014	180
Striving for Gender Equity in Academic Medicine Careers: A Call to Action Carol K. Bates, Lynn K. Gordon, Elizabeth L. Travis, Academic Medicine Women EmpowermentNursingAcademic Medicine CareersSystemic BarriersGender Disparity	2016	177
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Mark H. Einstein, Mira Baron, Myron J. Levin, Human Vaccines Observer-blind StudyImmunohematologyImmunodeficienciesImmunologyImmunodominance	2011	161
Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age Xavier Sáez‐Llorens, M. Macías, P. P. Maiya, Antimicrobial Agents and Chemotherapy NeonatologyCandida InfectionsInfant NutritionPharmacologyPediatrics	2008	138
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial Mark H. Einstein, Péter Takács, Archana Chatterjee, Human Vaccines & Immunotherapeutics	2014	125
Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Stan L. Block, Darron R. Brown, Archana Chatterjee, The Pediatric Infectious Disease Journal	2010	116
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years Mark H. Einstein, Mira Baron, Myron J. Levin, Human Vaccines	2011	114

Page 1